Intellectus Partners LLC Sells 2,650 Shares of UiPath Inc. (NYSE:PATH)

Intellectus Partners LLC trimmed its position in shares of UiPath Inc. (NYSE:PATH) by 14.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,907 shares of the healthcare company’s stock after selling 2,650 shares during the quarter. Intellectus Partners LLC’s holdings in UiPath were worth $204,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. acquired a new stake in UiPath during the 2nd quarter worth approximately $69,180,000. Vanguard Group Inc. boosted its stake in UiPath by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock worth $911,741,000 after purchasing an additional 2,133,078 shares during the period. Renaissance Technologies LLC bought a new position in UiPath during the 2nd quarter worth about $13,280,000. AQR Capital Management LLC lifted its holdings in shares of UiPath by 120.6% in the second quarter. AQR Capital Management LLC now owns 1,633,393 shares of the healthcare company’s stock valued at $20,385,000 after purchasing an additional 892,845 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of UiPath by 37.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,783,571 shares of the healthcare company’s stock valued at $35,296,000 after purchasing an additional 754,519 shares in the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

UiPath Stock Performance

NYSE:PATH opened at $12.37 on Friday. The firm has a market cap of $6.80 billion, a price-to-earnings ratio of -61.85 and a beta of 0.87. UiPath Inc. has a 52 week low of $10.37 and a 52 week high of $27.87. The firm’s 50-day simple moving average is $12.61 and its 200 day simple moving average is $13.42.

UiPath (NYSE:PATH) last released its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The company had revenue of $316.00 million during the quarter, compared to the consensus estimate of $303.69 million. During the same period in the previous year, the business earned ($0.09) earnings per share. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. Sell-side analysts anticipate that UiPath Inc. will post -0.23 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PATH. TD Cowen dropped their target price on UiPath from $17.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. BMO Capital Markets raised their price objective on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a report on Friday, September 6th. DA Davidson upped their price objective on UiPath from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. Royal Bank of Canada reissued a “sector perform” rating and issued a $16.00 target price on shares of UiPath in a research note on Friday, September 6th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $15.00 price objective on shares of UiPath in a research report on Friday, September 6th. Sixteen research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, UiPath has an average rating of “Hold” and an average target price of $17.47.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 47,671 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $12.07, for a total transaction of $575,388.97. Following the completion of the transaction, the chief financial officer now owns 849,917 shares of the company’s stock, valued at approximately $10,258,498.19. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.37% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.